Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy

Immunotherapy based on immune checkpoint inhibitors (ICIs) have demonstrated remarkable survival benefits and gained regulatory approval in non-small cell lung cancer (NSCLC) patients without an actionable driver mutation, but currently there is no well-established standard for how to screen the mos...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Mingyu, Zhang, Lu, Cui, Haiyan, Zhao, Qiang, Wang, Hao, Zhai, Baochao, Jiang, Richeng, Jiang, Zhansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770854/
https://www.ncbi.nlm.nih.gov/pubmed/35069585
http://dx.doi.org/10.3389/fimmu.2021.800951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770854/
https://www.ncbi.nlm.nih.gov/pubmed/35069585
http://dx.doi.org/10.3389/fimmu.2021.800951

Ejemplares similares